LLY

1,072.47

+0.53%↑

JNJ

230.78

-1.62%↓

ABBV

212.58

-1.64%↓

UNH

379.52

-2.23%↓

AZN

187.27

+0.01%↑

LLY

1,072.47

+0.53%↑

JNJ

230.78

-1.62%↓

ABBV

212.58

-1.64%↓

UNH

379.52

-2.23%↓

AZN

187.27

+0.01%↑

LLY

1,072.47

+0.53%↑

JNJ

230.78

-1.62%↓

ABBV

212.58

-1.64%↓

UNH

379.52

-2.23%↓

AZN

187.27

+0.01%↑

LLY

1,072.47

+0.53%↑

JNJ

230.78

-1.62%↓

ABBV

212.58

-1.64%↓

UNH

379.52

-2.23%↓

AZN

187.27

+0.01%↑

LLY

1,072.47

+0.53%↑

JNJ

230.78

-1.62%↓

ABBV

212.58

-1.64%↓

UNH

379.52

-2.23%↓

AZN

187.27

+0.01%↑

Home・Stock List・Twist Bioscience Corp

Twist Bioscience Corp

Open

SectorHealthcare

64.4 6.91

Buy Sell

Overview

Share price change

24h

Current

Min

60.6

Max

65.51

Key metrics
By Trading Economics
Income	-14M -44M
Sales	7M 111M
EPS	-0.597
Profit margin	-39.761
Employees	979
EBITDA	-16M -40M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+4.72% upside

Dividends
By Dow Jones
Next Earnings	3 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-345M 3.1B
Previous open	57.49
Previous close	64.4

News Sentiment

By Acuity

38%

62%

114 / 345 Healthcare

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

25 May 2026, 08:24 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 May 2026, 21:22 UTC

Earnings

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 May 2026, 20:50 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 May 2026, 16:20 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 May 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 May 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 May 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 May 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 May 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 May 2026, 12:56 UTC

Market Talk

Earnings

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 May 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 May 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25 May 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 May 2026, 12:10 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Delivery Hero's Assets Look Strategic -- Market Talk

25 May 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 May 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 May 2026, 10:05 UTC

Earnings

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 May 2026, 10:04 UTC

Earnings

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 May 2026, 10:03 UTC

Earnings

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 May 2026, 10:02 UTC

Earnings

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 May 2026, 10:01 UTC

Earnings

Tenaga Nasional 1Q Net Up 3.7% on Year

25 May 2026, 10:00 UTC

Earnings

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q EPS MYR0.1883

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Rev MYR17.1B

25 May 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Net MYR1.1B

25 May 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 May 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25 May 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 May 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

4.72% upside

12 Months Forecast

Average 63.43 USD 4.72%

High 70 USD

Low 56 USD

Based on 7 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Twist Bioscience Corp - Dist in the past 3 months.

Sentiment

By Acuity

114 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.